𝔖 Bobbio Scriptorium
✦   LIBER   ✦

SORAFENIB PLUS INTERFERON-α2A IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM RAPSODY (GOIRC STUDY 0681), A RANDOMISED PROSPECTIVE PHASE II TRIAL OF TWO DIFFERENT TREATMENT SCHEDULES

✍ Scribed by S. Bracarda; C. Porta; C. Boni; A. Santoro; F. Artioli; A. Contu; L. Mentuccia; D. Gasparro; C. Caserta; V. De Angelis

Book ID
119619024
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
74 KB
Volume
7
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subcutaneous interleukin-2 and interfero
Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie
✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a

Interleukin-2, interferon-α, 5-fluoroura
Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma : A prospective Phase II study: The experience of Rambam and Lin Medical Centers 1996-2000
✍ Eliahu Gez; Raphael Rubinov; Diana Gaitini; Shimon Meretyk; Lael-Anson Best; Ofe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive

Interferon-α-2a with or without 13-cis r
Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)
✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin